Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis  

作　　者：Qian Zhao Jiale Dong Han Liu Hui Chen Huan Yu Shuyin Ye Shuangjin Yu Yu Li Longhui Qiu Nazi Song Hongjiao Xu Qi Liu Zhiteng Luo Yuyi Li Rui Wang Guodong Chen Xianxing Jiang 

机构地区：[1]School of Pharmaceutical Sciences,Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery,Sun Yat-sen University,Guangzhou 510006,China [2]Organ Transplant Center,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510006,China [3]Zhongshan School of Medicine,Sun Yat-sen University,Guangzhou 510006,China [4]Shenzhen Turier Biotech.Co.,Ltd.,Shenzhen 518118,China [5]School of Life Sciences,Key Laboratory of Preclinical Study for New Drugs of Gansu Province,School of Basic Medical Sciences&Research Unit of Peptide Science,Chinese Academy of Medical Sciences,Lanzhou University,Lanzhou 730000,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第3期1283-1301,共19页药学学报（英文版）

基　　金：financial support from the National Natural Science Foundation of China(No.82273761 and No.81871257);the Medical Innovation and Development Project of Lanzhou University(lzuyxcx-2022-156,China);the Undergraduate Teaching Quality Engineering Project of Sun Yat-sen University[2021]93;the Guangdong Provincial Key Laboratory of Construction Foundation(2023B1212060022,China)。

摘　　要：The role of co-agonists of glucagon-like peptide-1 receptor(GLP-1R)and glucagon receptor(GCGR)in chronic kidney disease(CKD)remains unclear.Herein we found that GLP-1R and GCGR expression levels were lower in the kidneys of mice with CKD compared to healthy mice and were correlated with disease severity.Interestingly,GLP-1R or GCGR knockdown aggravated the progression of kidney injury in both diabetic db/db mice and non-diabetic mice undergoing unilateral ureteral obstruction(UUO).Based on the importance of GLP-1R and GCGR in CKD,we reported a novel monomeric peptide,1907-B,with dual-agonism on both GLP-1R and GCGR.The data confirmed that 1907-B had a longer half-life than long-acting semaglutide in rats or cynomolgus monkeys(~2-3 fold)and exhibited better therapeutic contribution to CKD than best-in-class monoagonists,semaglutide,or glucagon,in db/db mice and UUO mice.Various lock-of-function models,including selective pharmacological activation and genetic knockdown,confirmed that 1907-B’s effects on ameliorating diabetic nephropathy in db/db mice,as well as inhibiting kidney fibrosis in UUO mice,were mediated through GLP-1 and glucagon signaling.These findings highlight that 1907-B,a novel GLP-1R and GCGR co-agonist,exerts multifactorial improvement in kidney injuries and is an effective and promising therapeutic option for CKD treatment.

关 键 词：GLP-1 receptor Glucagon receptor Chronic kidney disease Diabetic nephropathy Kidney fibrosis Dual-agonism 

分 类 号：R692[医药卫生—泌尿科学]